Provectus Biopharmaceuticals, Inc. (PVCT)
USD 0.13
(-0.76%)
USD 0.13
(-0.76%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.02 Million USD | 38.52% |
| 2022 | 2.18 Million USD | 25.26% |
| 2021 | 1.74 Million USD | -92.67% |
| 2020 | 23.79 Million USD | 16.8% |
| 2019 | 20.37 Million USD | 46.24% |
| 2018 | 13.93 Million USD | 47.34% |
| 2017 | 9.45 Million USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 364.7 Thousand USD | -58.51% |
| 2005 | 878.94 Thousand USD | -47.49% |
| 2004 | 1.67 Million USD | 42.41% |
| 2003 | 1.17 Million USD | 18.88% |
| 2002 | 988.65 Thousand USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 3.04 Million USD | -4.63% |
| 2024 Q1 | 3.19 Million USD | 5.6% |
| 2023 FY | 3.02 Million USD | 38.52% |
| 2023 Q3 | 3.15 Million USD | 10.83% |
| 2023 Q2 | 2.84 Million USD | 7.85% |
| 2023 Q1 | 2.63 Million USD | 20.83% |
| 2023 Q4 | 3.02 Million USD | -4.1% |
| 2022 Q2 | 2.29 Million USD | 36.15% |
| 2022 FY | 2.18 Million USD | 25.26% |
| 2022 Q1 | 1.68 Million USD | -3.49% |
| 2022 Q4 | 2.18 Million USD | -19.7% |
| 2022 Q3 | 2.72 Million USD | 18.72% |
| 2021 Q1 | 24.89 Million USD | 4.63% |
| 2021 Q3 | 331.31 Thousand USD | 54.55% |
| 2021 FY | 1.74 Million USD | -92.67% |
| 2021 Q2 | 214.36 Thousand USD | -99.14% |
| 2021 Q4 | 1.74 Million USD | 426.41% |
| 2020 Q1 | 20.65 Million USD | 1.38% |
| 2020 FY | 23.79 Million USD | 16.8% |
| 2020 Q2 | 22.87 Million USD | 10.74% |
| 2020 Q3 | 23.47 Million USD | 2.65% |
| 2020 Q4 | 23.79 Million USD | 1.36% |
| 2019 Q4 | 20.37 Million USD | 4.93% |
| 2019 Q3 | 19.41 Million USD | 2.06% |
| 2019 FY | 20.37 Million USD | 46.24% |
| 2019 Q1 | 17.99 Million USD | 29.15% |
| 2019 Q2 | 19.02 Million USD | 5.74% |
| 2018 Q3 | 13.36 Million USD | 8.09% |
| 2018 FY | 13.93 Million USD | 47.34% |
| 2018 Q4 | 13.93 Million USD | 4.27% |
| 2018 Q1 | 10.91 Million USD | 15.4% |
| 2018 Q2 | 12.36 Million USD | 13.29% |
| 2017 Q2 | 5.55 Million USD | 122.0% |
| 2017 Q1 | 2.5 Million USD | 0.0% |
| 2017 Q3 | 7.1 Million USD | 27.93% |
| 2017 FY | 9.45 Million USD | 0.0% |
| 2017 Q4 | 9.45 Million USD | 33.18% |
| 2016 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q1 | - USD | -100.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 FY | - USD | -100.0% |
| 2006 Q2 | 486.47 Thousand USD | -38.17% |
| 2006 Q1 | 786.74 Thousand USD | -10.49% |
| 2006 FY | 364.7 Thousand USD | -58.51% |
| 2006 Q4 | 364.7 Thousand USD | -27.26% |
| 2006 Q3 | 501.38 Thousand USD | 3.07% |
| 2005 Q3 | 1.57 Million USD | -21.18% |
| 2005 Q4 | 878.94 Thousand USD | -44.09% |
| 2005 FY | 878.94 Thousand USD | -47.49% |
| 2005 Q1 | 1.74 Million USD | 4.06% |
| 2005 Q2 | 1.99 Million USD | 14.51% |
| 2004 Q4 | 1.67 Million USD | 28.65% |
| 2004 Q3 | 1.3 Million USD | -12.27% |
| 2004 Q1 | 1.31 Million USD | 11.92% |
| 2004 Q2 | 1.48 Million USD | 12.73% |
| 2004 FY | 1.67 Million USD | 42.41% |
| 2003 FY | 1.17 Million USD | 18.88% |
| 2003 Q4 | 1.17 Million USD | 6.67% |
| 2003 Q3 | 1.1 Million USD | 5.35% |
| 2003 Q2 | 1.04 Million USD | 1.53% |
| 2003 Q1 | 1.03 Million USD | 4.2% |
| 2002 Q1 | - USD | -100.0% |
| 2002 FY | 988.65 Thousand USD | 0.0% |
| 2002 Q3 | 6000.00 USD | 20.0% |
| 2002 Q2 | 5000.00 USD | 0.0% |
| 2002 Q4 | 988.65 Thousand USD | 16377.6% |
| 2001 Q1 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | 2100.00 USD | -38.24% |
| 2001 Q3 | 3400.00 USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 92.655% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 26.584% |
| SQZ Biotechnologies Company | 27.47 Million USD | 88.984% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 93.023% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 89.834% |
| Mesoblast Limited | 118.7 Million USD | 97.451% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -219.127% |
| Genus plc | 233.1 Million USD | 98.702% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -3.269% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -125.233% |
| Marizyme, Inc. | 18.71 Million USD | 83.832% |
| ContraFect Corporation | 2.88 Million USD | -5.04% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -303.492% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -2133.566% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -109.234% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -30.105% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 46.518% |
| MultiCell Technologies, Inc. | 202.58 USD | -1493725.155% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 94.736% |
| EV Biologics, Inc. | 1.49 Million USD | -102.455% |
| Q BioMed Inc. | 4.1 Million USD | 26.37% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 90.858% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -380.289% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -146.36% |
| Biomind Labs Inc. | 735.54 Thousand USD | -311.423% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 98.236% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 76.716% |
| Skye Bioscience, Inc. | 4.61 Million USD | 34.431% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -240.763% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -2038.379% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 48.456% |
| IMV Inc. | 28.88 Million USD | 89.523% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -11666.363% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -33.998% |
| GB Sciences, Inc. | 1.75 Million USD | -72.01% |
| Alpha Cognition Inc. | 1.22 Million USD | -147.973% |
| HST Global, Inc. | 98.31 Thousand USD | -2977.931% |
| CSL Limited | 12.18 Billion USD | 99.975% |
| Halberd Corporation | 150 Thousand USD | -1917.461% |
| Enzolytics Inc. | 996.33 Thousand USD | -203.731% |
| Resverlogix Corp. | 6.49 Million USD | 53.379% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -533.757% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1083.993% |
| argenx SE | 20 Million USD | 84.869% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 93.358% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -11.721% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -29496.0% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.276% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1408.449% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -26.211% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1219.804% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 95.526% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -741.286% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 85.113% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -1935.728% |
| BioStem Technologies, Inc. | 4.71 Million USD | 35.769% |
| ONE Bio Corp. | 19.71 Million USD | 84.65% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1109.596% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1116.706% |
| Agentix Corp. | 50 Thousand USD | -5952.382% |
| LadRx Corporation | 33.6 Thousand USD | -8904.913% |
| Cell Source, Inc. | 9.25 Million USD | 67.299% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -300.182% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -300.182% |
| NovAccess Global Inc. | 2.19 Million USD | -37.562% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 57.214% |
| Itoco Inc. | 228.37 Thousand USD | -1225.086% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1334.384% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 39.27% |
| Kadimastem Ltd | 891.22 Thousand USD | -239.554% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -653.067% |
| CytoDyn Inc. | 30.07 Million USD | 89.938% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -524.879% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -760.087% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 61.302% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -2370.36% |
| Rebus Holdings, Inc. | 310 Thousand USD | -876.191% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 36.093% |
| International Stem Cell Corporation | 4.17 Million USD | 27.568% |
| Bioxytran, Inc. | 1.92 Million USD | -57.205% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -4748.655% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -38.759% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 63.61% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 64.75% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -94.55% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1029.176% |
| Neutra Corp. | 54.15 Thousand USD | -5487.915% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -65.366% |
| PureTech Health plc | 25.51 Million USD | 88.138% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -147.192% |
| IXICO plc | 472.02 Thousand USD | -541.111% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 80.477% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 95.14% |
| CSL Limited | 12.18 Billion USD | 99.975% |
| Cellectis S.A. | 92.77 Million USD | 96.738% |